VIENNA, Austria — The appropriate dose of pancreatic enzyme replacement therapy (PERT) for exocrine pancreatic insufficiency (EPI) depends on the root cause of the insufficiency, according to results ...
ABBOTT PARK, Ill., June 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON® (pancrelipase) ...
Enzyme replacement for Gaucher disease (GD) has now been available for 17 years. This therapy, the first enzyme preparation developed for the treatment of a lysosomal storage disorder, has ...
A look at the formulation challenges in pancreatic enzyme products. Specialty pharmaceuticals are an important component of the pharmaceutical market. They are broadly defined as drugs that target a ...
Degenerative joint changes have been reported in human mucopolysaccharidosis VI (MPS VI) and are a prominent feature of feline MPS VI. Joint disease has proven refractory to intravenous enzyme ...
Please provide your email address to receive an email when new articles are posted on . Over the past 5 years, several studies have been published describing how oral liquid drug dosing devices and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results